Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association

被引:3
|
作者
Johnson, Keith A. [1 ,2 ]
Minoshima, Satoshi [3 ]
Bohnen, Nicolaas I. [4 ,5 ,6 ]
Donohoe, Kevin J. [7 ]
Foster, Norman L. [8 ]
Herscovitch, Peter [9 ]
Karlawish, Jason H. [10 ]
Rowe, Christopher C. [11 ,12 ]
Carrillo, Maria C. [13 ]
Hartley, Dean M. [13 ]
Hedrick, Saima [14 ]
Pappas, Virginia [14 ]
Thies, William H. [13 ]
机构
[1] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA
[2] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA
[3] Univ Washington, Dept Radiol, Seattle, WA 98195 USA
[4] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA
[5] Univ Michigan, Dept Neurol, Ann Arbor, MI USA
[6] VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA
[7] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[8] Univ Utah, Dept Neurol, Salt Lake City, UT USA
[9] NIH, PET Dept, Ctr Clin, Bethesda, MD 20892 USA
[10] Univ Penn, Dept Med, Philadelphia, PA 19104 USA
[11] Austin Hlth, Dept Nucl Med, Heidelberg, Vic, Australia
[12] Austin Hlth, Ctr PET, Heidelberg, Vic, Australia
[13] Alzheimers Assoc, Div Med & Sci Relat, Chicago, IL 60631 USA
[14] Soc Nucl Med & Mol Imaging, Reston, VA USA
关键词
Guidelines; AUC; Imaging; Amyloid; MCI; Alzheimer's; PET; Florbetapir; Biomarker; Beta-amyloid; Dementia; Radiopharmaceutical;
D O I
10.1016/j.jalz.2013.01.002
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Positron emission tomography (PET) of brain amyloid beta is a technology that is becoming more available, but its clinical utility in medical practice requires careful definition. To provide guidance to dementia care practitioners, patients, and caregivers, the Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging convened the Amyloid Imaging Taskforce (AIT). The AIT considered a broad range of specific clinical scenarios in which amyloid PET could potentially be used appropriately. Peer-reviewed, published literature was searched to ascertain available evidence relevant to these scenarios, and the AIT developed a consensus of expert opinion. Although empirical evidence of impact on clinical outcomes is not yet available, a set of specific appropriate use criteria (AUC) were agreed on that define the types of patients and clinical circumstances in which amyloid PET could be used. Both appropriate and inappropriate uses were considered and formulated, and are reported and discussed here. Because both dementia care and amyloid PET technology are in active development, these AUC will require periodic reassessment. Future research directions are also outlined, including diagnostic utility and patient-centered outcomes. (C) 2013 The Alzheimer's Association. All rights reserved.
引用
收藏
页码:E1 / E16
页数:16
相关论文
共 50 条
  • [1] Appropriate Use Criteria for Amyloid PET: A Report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association
    Johnson, Keith A.
    Minoshima, Satoshi
    Bohnen, Nicolaas I.
    Donohoe, Kevin J.
    Foster, Norman L.
    Herscovitch, Peter
    Karlawish, Jason H.
    Rowe, Christopher C.
    Carrillo, Maria C.
    Hartley, Dean M.
    Hedrick, Saima
    Pappas, Virginia
    Thies, William H.
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (03) : 476 - 490
  • [2] Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
    Rabinovici, Gil D.
    Knopman, David S.
    Arbizu, Javier
    Benzinger, Tammie L. S.
    Donohoe, Kevin J.
    Hansson, Oskar
    Herscovitch, Peter
    Kuo, Phillip H.
    Lingler, Jennifer H.
    Minoshima, Satoshi
    Murray, Melissa E.
    Price, Julie C.
    Salloway, Stephen P.
    Weber, Christopher J.
    Carrillo, Maria C.
    Johnson, Keith A.
    ALZHEIMERS & DEMENTIA, 2025, 21 (01)
  • [3] Appropriate use criteria for amyloid PET imaging cannot replace guidelines: On behalf of the European Association of Nuclear Medicine
    Booij, Jan
    Arbizu, Javier
    Darcourt, Jacques
    Hesse, Swen
    Nobili, Flavio
    Payoux, Pierre
    Pappata, Sabina
    Tatsch, Klaus
    Walker, Zuzana
    Pagani, Marco
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (07) : 1122 - 1125
  • [4] Appropriate use criteria for amyloid PET imaging cannot replace guidelines: On behalf of the European Association of Nuclear Medicine
    Jan Booij
    Javier Arbizu
    Jacques Darcourt
    Swen Hesse
    Flavio Nobili
    Pierre Payoux
    Sabina Pappatà
    Klaus Tatsch
    Zuzana Walker
    Marco Pagani
    European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40 : 1122 - 1125
  • [5] Quantitative appraisal of the Amyloid Imaging Taskforce appropriate use criteria for amyloid-PET
    Altomare, Daniele
    Ferrari, Clarissa
    Festari, Cristina
    Guerra, Ugo Paolo
    Muscio, Cristina
    Padovani, Alessandro
    Friso, Giovanni B.
    Boccardi, Marina
    ALZHEIMERS & DEMENTIA, 2018, 14 (08) : 1088 - 1098
  • [6] PET imaging of amyloid in Alzheimer's disease
    Nordberg, A
    LANCET NEUROLOGY, 2004, 3 (09): : 519 - 527
  • [7] Cerebral amyloid PET imaging in Alzheimer's disease
    Jack, Clifford R., Jr.
    Barrio, Jorge R.
    Kepe, Vladimir
    ACTA NEUROPATHOLOGICA, 2013, 126 (05) : 643 - 657
  • [8] Cerebral amyloid PET imaging in Alzheimer’s disease
    Clifford R. Jack
    Jorge R. Barrio
    Vladimir Kepe
    Acta Neuropathologica, 2013, 126 : 643 - 657
  • [9] Appropriate use criteria for dementia amyloid imaging in Switzerland - mini-review and statement on behalf of the Swiss Society of Nuclear Medicine and the Swiss Memory Clinics
    Juengling, Freimut Dankwart
    Allenbach, Gilles
    Bruehlmeier, Matthias
    Klaeser, Bernd
    Wissmeyer, Michael Peter
    Garibotto, Valentina
    Felbecker, Ansgar
    Georgescu, Dan
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2021, 60 (01): : 7 - 9
  • [10] German Society of Nuclear Medicine procedure guideline on beta-amyloid brain PET imaging
    Barthel, Henryk
    Meyer, Philipp T.
    Drzezga, Alexander
    Bartenstein, Peter
    Boecker, Henning
    Brust, Peter
    Buchert, Ralph
    Coenen, Heinz. H.
    la Fougere, Christian
    Gruender, Gerhard
    Gruenwald, Frank
    Krause, Bernd J.
    Kuwert, Torsten
    Schreckenberger, Matthias
    Tatsch, Klaus
    Langen, Karl-Josef
    Sabri, Osama
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2016, 55 (04): : 129 - 137